New research led by a pediatric oncology expert from Roswell Park Comprehensive Cancer Center underscores that diets high in antioxidant-rich foods can have particular benefits for young cancer patients.
Aggressive forms of prostate cancer don’t act the way they should, hanging on to genetic materials called introns that should be thrown away, researchers from Roswell Park reported today in Nature Communications.
Radiation is one of the oldest and most common therapies for cancer, and typically is delivered locally, or to specific targeted sites in the body. While it has long been thought that locally-delivered radiation therapy typically does not help to shrink tumors outside the field of irradiation, new preclinical research from a team at Roswell Park Comprehensive Cancer Center suggests a strategy for significantly increasing both the local and distant, or “abscopal,” effects of radiation. Results of the study, which was led by Elizabeth Repasky, PhD, have been newly published in Nature Communications.
Roswell Park will offer plasma from the donated blood of healthy individuals who have had COVID-19 but have now fully recovered to patients with severe or life-threatening COVID-19 through an expanded access program authorized by the U.S. FDA.
New research from Roswell Park Comprehensive Cancer Center, published in the Journal of the National Cancer Institute, shows that following those guidelines can improve clinical outcomes for patients with high-risk breast cancer, or breast cancer that is likely to recur or spread.
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant program, this prestigious five-year grant will fund five clinical trials, all focused on a strategy for making some of the most common immunotherapies work for more cancer patients.
A Roswell Park team has identified a new strategy for treating prostate cancer — the first to target metabolic processes uniquely important to prostate cancer.
A team of researchers from Roswell Park Comprehensive Cancer Center and the CDC report new evidence that inhalation of vitamin E acetate is strongly linked to e-cigarette, or vaping, product use-associated lung injury (EVALI).
A research team led by Dr. Dean Tang at Roswell Park Comprehensive Cancer Center has identified the molecule LRIG1 as an important endogenous tumor suppressor in prostate cancer.
The inventors of a cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, SurVaxM — a multimillion-dollar licensing deal that will help enable large, randomized clinical trials in both the U.S. and China.
Roswell Park's Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.
In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.
A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a DoD grant that will fund a clinical trial in patients with brain-metastatic breast cancer.
Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.
Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.
Researchers from Roswell Park have developed a new bioinformatics-based approach for monitoring key changes in cancer cells — a data-driven method that might help to enhance and personalize cancer treatment.
A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.
Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.
With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.
A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right